PALISADE BIO, INC. (PALI) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$11.70M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$10.75M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$2.92M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$2.84M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$11.70M | (m) | $500.00K | (m) | (m) | -$7.60M* | (m) | $6.00M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$10.75M | (m) | (m) | (m) | (m) | -$3.89M | (m) | $6.00M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$2.92M | (m) | (m) | (m) | (m) | -$3.55M* | (m) | (m) | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$2.84M | (m) | $0.00 | (m) | (m) | -$1.82M* | (m) | (m) | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$2.31M | (m) | (m) | (m) | (m) | -$2.33M | (m) | (m) | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$3.59M | (m) | $0.00 | (m) | $0.00* | -$3.13M* | (m) | $16.00M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$4.21M | (m) | $0.00 | (m) | (m) | -$3.50M* | (m) | (m) | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$3.67M | (m) | $0.00 | (m) | (m) | -$3.18M | (m) | (m) | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$3.78M | (m) | $0.00 | (m) | $0.00* | -$2.66M* | (m) | (m) | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$3.61M | (m) | $0.00 | (m) | (m) | -$2.20M* | (m) | (m) | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$2.53M | (m) | $250.00K | (m) | (m) | -$3.53M | (m) | (m) | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$4.41M | (m) | $0.00 | (m) | $0.00* | -$3.04M* | (m) | (m) | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$3.57M | (m) | $0.00 | (m) | (m) | -$3.25M* | (m) | (m) | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$3.89M | (m) | $0.00 | (m) | (m) | -$3.76M | (m) | (m) | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$3.02M | (m) | (m) | (m) | $0.00* | -$2.75M* | (m) | (m) | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$32.86M | (m) | (m) | (m) | (m) | -$7.72M* | (m) | (m) | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$1.95M | (m) | (m) | (m) | (m) | -$1.25M | (m) | $471.11K | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$1.82M | (m) | (m) | (m) | -$1.00K* | -$869.00K* | (m) | $466.01K | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$1.84M | (m) | (m) | (m) | (m) | -$673.37K* | (m) | $446.03K | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$1.99M | (m) | (m) | (m) | (m) | -$1.68M | (m) | $696.89K | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$2.12M | (m) | (m) | (m) | (m) | -$1.90M* | (m) | $825.49K | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$1.92M | (m) | (m) | (m) | (m) | -$1.64M* | (m) | $954.45K | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$2.46M | (m) | (m) | (m) | (m) | -$1.67M | (m) | $1.51M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$2.08M | (m) | (m) | (m) | (m) | -$1.66M* | (m) | $897.10K | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$2.02M | (m) | (m) | (m) | (m) | -$2.52M* | (m) | $1.01M | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$2.35M | (m) | (m) | (m) | (m) | -$1.85M | (m) | $1.17M | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$2.59M | (m) | (m) | (m) | $1.32K* | -$3.32M* | (m) | $1.38M | (m) | (m) |
| 2017-06-30 | Reported | (m) | -$4.22M | (m) | (m) | (m) | (m) | -$3.37M* | (m) | $2.59M | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$4.23M | (m) | (m) | (m) | (m) | -$4.44M | (m) | $2.90M | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$4.92M | (m) | (m) | (m) | $0.00* | (m) | (m) | $3.59M | (m) | (m) |
| 2016-06-30 | Reported | (m) | -$3.83M | (m) | (m) | (m) | $83.49K* | (m) | (m) | $2.47M | (m) | (m) |
| 2016-03-31 | Reported | (m) | -$6.23M | (m) | (m) | (m) | $14.60K | (m) | (m) | $3.07M | (m) | (m) |
| 2015-12-31 | Reported | (m) | -$4.35M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$5.20M | (m) | (m) | (m) | $32.19K* | (m) | (m) | $3.39M | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$5.20M | (m) | (m) | (m) | (m) | (m) | (m) | $3.39M | (m) | (m) |
| 2015-06-30 | Reported | (m) | -$4.99M | (m) | (m) | (m) | $79.97K* | (m) | (m) | $3.31M | (m) | (m) |
| 2015-03-31 | Reported | (m) | -$4.61M | (m) | (m) | (m) | $16.05K | (m) | (m) | $3.18M | (m) | (m) |
| 2014-12-31 | Reported | (m) | -$4.64M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$4.11M | (m) | (m) | (m) | $27.08K* | (m) | (m) | $2.11M | (m) | (m) |
| 2014-06-30 | Reported | (m) | -$3.51M | (m) | (m) | (m) | $34.00K* | (m) | (m) | $2.00M | (m) | (m) |
| 2014-03-31 | Reported | (m) | -$5.18M | (m) | (m) | (m) | $111.09K | (m) | (m) | $1.63M | (m) | (m) |
| 2013-12-31 | Reported | (m) | -$2.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | Reported | (m) | -$3.63M | (m) | (m) | (m) | $113.55K* | -$2.24M* | (m) | $1.85M | (m) | (m) |
| 2013-06-30 | Reported | (m) | -$3.24M | (m) | (m) | (m) | $3.74K* | -$3.36M* | (m) | $1.91M | (m) | (m) |
| 2013-03-31 | Reported | (m) | -$2.89M | (m) | (m) | (m) | $1.66K | -$2.51M | (m) | $1.75M | (m) | (m) |
| 2012-12-31 | Reported | (m) | -$2.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | Reported | (m) | -$2.58M | (m) | (m) | (m) | $593.00* | -$1.42M* | (m) | $1.39M | (m) | (m) |
| 2012-06-30 | Reported | (m) | -$2.38M | (m) | (m) | (m) | $29.61K* | -$2.44M* | (m) | $1.60M | (m) | (m) |
| 2012-03-31 | Reported | (m) | -$2.46M | (m) | (m) | (m) | $0.00 | -$2.10M | (m) | $1.42M | (m) | (m) |
| 2011-09-30 | Reported | (m) | -$3.22M | (m) | (m) | (m) | $5.13K* | -$1.81M* | (m) | $2.12M | (m) | (m) |
| 2011-06-30 | Reported | (m) | -$3.67M | (m) | (m) | (m) | $131.79K* | -$2.21M* | (m) | $2.09M | (m) | (m) |
| 2011-03-31 | Reported | (m) | -$3.54M | (m) | (m) | (m) | $50.17K | -$2.29M | (m) | $1.74M | (m) | (m) |
| 2010-09-30 | Reported | (m) | -$3.92M | (m) | (m) | (m) | $1.59K* | -$2.35M* | (m) | $2.11M | (m) | (m) |
| 2010-06-30 | Reported | (m) | -$4.20M | (m) | (m) | (m) | (m) | (m) | (m) | $2.61M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$18.06M | (m) | (m) | (m) | (m) | -$10.85M | (m) | (m) | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$14.86M | (m) | $0.00 | (m) | $0.00 | -$12.19M | (m) | $16.00M | (m) | $0.00 |
| 2023-12-31 | Reported | (m) | -$13.07M | (m) | $250.00K | (m) | $4.00K | -$11.13M | (m) | (m) | (m) | $0.00 |
| 2022-12-31 | Reported | (m) | -$15.72M | (m) | $0.00 | (m) | $10.00K | -$13.36M | (m) | (m) | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | -$41.85M | (m) | (m) | (m) | $0.00 | -$14.77M | (m) | (m) | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | -$9.30M | (m) | (m) | (m) | $6.00K | -$4.77M | (m) | $2.02M | (m) | $1.00K |
| 2019-12-31 | Reported | (m) | -$8.63M | (m) | (m) | (m) | (m) | -$7.26M | (m) | $4.06M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$8.26M | (m) | (m) | (m) | $1.71K | -$7.69M | (m) | $3.96M | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$13.31M | (m) | (m) | (m) | $11.40K | -$13.42M | (m) | $8.10M | (m) | (m) |
| 2016-12-31 | Reported | (m) | -$20.64M | (m) | (m) | (m) | $98.09K | -$15.62M | (m) | $13.16M | (m) | $0.00 |
| 2016-09-30 | Rolling | (m) | -$19.34M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | Reported | (m) | -$19.16M | (m) | (m) | (m) | $176.27K | (m) | (m) | $12.64M | (m) | $0.00 |
| 2015-06-30 | Rolling | (m) | -$18.36M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | Rolling | (m) | -$16.87M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | Reported | (m) | -$17.44M | (m) | (m) | (m) | $207.89K | (m) | (m) | $8.36M | (m) | $0.00 |
| 2014-12-31 | Rolling | (m) | -$17.44M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | Rolling | (m) | -$15.56M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | Rolling | (m) | -$15.08M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | Rolling | (m) | -$14.81M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | Reported | (m) | -$12.52M | (m) | (m) | (m) | $125.36K | (m) | (m) | $7.29M | (m) | $0.00 |
| 2013-12-31 | Rolling | (m) | -$12.52M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | Rolling | (m) | -$12.49M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | Rolling | (m) | -$11.44M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | Rolling | (m) | -$10.59M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | Reported | (m) | -$10.16M | (m) | (m) | (m) | $39.22K | -$8.48M | (m) | $6.11M | $256.00K | $0.00 |
| 2012-12-31 | Rolling | (m) | -$10.16M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | Reported | (m) | -$12.99M | (m) | (m) | (m) | $196.41K | -$8.10M | (m) | $7.35M | $256.00K | $0.00 |
| 2010-12-31 | Reported | (m) | -$15.18M | (m) | (m) | (m) | $76.32K | -$9.98M | (m) | $9.16M | (m) | (m) |
| 2009-12-31 | Reported | (m) | -$10.47M | (m) | (m) | (m) | $88.38K | -$5.14M | (m) | $5.35M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |